DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL
Clinical Trials for Candesartan Cilexetil
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00108706 | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Unknown status | Takeda | Phase 4 | The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke. |
| NCT00108706 | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Unknown status | City Hospitals Sunderland NHS Foundation Trust | Phase 4 | The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke. |
| NCT00125463 | Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients | Unknown status | The Japanese Society of Hypertension | Phase 3 | The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil– Blopress®) and a calcium channel blocker (amlodipine besilate– Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients. |
| NCT00139386 | Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial | Completed | Japan Heart Foundation | Phase 4 | Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation. |
| NCT00139386 | Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial | Completed | The 4C trial bureau | Phase 4 | Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Candesartan Cilexetil
Condition Name
Clinical Trial Locations for Candesartan Cilexetil
Trials by Country
Clinical Trial Progress for Candesartan Cilexetil
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Candesartan Cilexetil
Sponsor Name
